2-[(4-Oxo-3-phenyl-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)sulfanyl]acetamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 英文名称: 2-[(4-Oxo-3-phenyl-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)sulfanyl]acetamide
• 化学式: C₁₄H₁₃N₃O₂S₂
• 分子量: 319.4
• InChiKey: KNOQUEZIOZOYMM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  126
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Disubstituted and trisubstituted 1,2,3-triazoles as Wnt inhibitors
  申请人：The Board of Regents of the University of Texas System

  公开号：US10793544B2

  公开（公告）日：2020-10-06

  The present disclosure provides compounds that may be useful for inhibiting Wnt pathway comprising compounds of the formula: (Ia) or (Ib) wherein the variables are as defined herein. In some aspects, the compounds may be used to inhibit the Wnt pathway and used to treat cancer, myocardial infarction, osteopetrosis, or used in the maturation of a precursor cell to a mature cell. Also provided herein in are pharmaceutical compositions of the compounds described herein.

  本公开提供了可用于抑制 Wnt 通路的化合物，其中包括式：(Ia)或(Ib)，其中变量如本文所定义。在某些方面，这些化合物可用于抑制 Wnt 通路，并用于治疗癌症、心肌梗塞、骨质疏松，或用于前体细胞向成熟细胞的成熟。本文还提供了本文所述化合物的药物组合物。
• DISUBSTITUTED AND TRISUBSTITUTED 1,2,3-TRIAZOLES AS WNT INHIBITORS
  申请人：The Board of Regents of the University of Texas System

  公开号：US20190202804A1

  公开（公告）日：2019-07-04

  The present disclosure provides compounds that may be useful for inhibiting Wnt pathway comprising compounds of the formula: (Ia) or (Ib) wherein the variables are as defined herein. In some aspects, the compounds may be used to inhibit the Wnt pathway and used to treat cancer, myocardial infarction, osteopetrosis, or used in the maturation of a precursor cell to a mature cell. Also provided herein in are pharmaceutical compositions of the compounds described herein.
• [EN] WNT PROTEIN SIGNALLING INHIBITORS<br/>[FR] INHIBITEURS DE LA SIGNALISATION PAR LA PROTÉINE WNT
  申请人：UNIV TEXAS

  公开号：WO2013169631A2

  公开（公告）日：2013-11-14

  The present invention generally relates to protein signalling. In particular, compounds that inhibit the Wnt protein signalling pathway are disclosed. Such compounds may be used in the treatment of Wnt protein signalling-related diseases and conditions such as cancer, degenerative diseases, type II diabetes and osteopetrosis.